Selective IgE immune apheresis hits market
Help for patients with IgE-mediated diseases
Biomay AG announced that CE mark designation has been achieved for a medical device indicated for the treatment of IgE-mediated diseases, which has been co-developed by the company together with a medical device manufacturer.
The product is an immune apheresis column which contains a single chain antibody fragment with very high affinity to human IgE, covalently linked to a solid support. The antibody ligand has been discovered in the laboratory of Prof. Rudolf Valenta at the Medical University of Vienna; Biomay holds the patent rights. Process development and GMP manufacturing of the affinity ligand has been performed by Biomay, while the device itself is manufactured and will be marketed by the development partner.
In a recently completed clinical trial the device has been shown to very efficiently and selectively remove IgE from the plasma of patients with allergic asthma. This trial was the basis of CE mark approval.
Biomay has already received several milestone payments and is entitled to royalties on sales.
Other news from the department research and development
